Meghmani Finechem informs about outcome of board meeting

20 Oct 2022 Evaluate
Meghmani Finechem has informed that the Board of Directors of the Company at its meeting held on 20th October, 2022, have considered and approved Unaudited Financial Results (Consolidated & Standalone) of the Second Quarter/ Half year ended on 30th September, 2022 prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which were reviewed by Audit Committee and approved by Board of Directors at their meeting held on 20th October, 2022 is forwarded. The Statutory Auditors S R B C & CO LLP, Chartered Accountants have carried out a limited review Report on Un-audited Financial Results (Consolidated & Standalone) of the Second Quarter/Half year ended 30th September, 2022 with unmodified opinion and the same is also forwarded.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1468.90 -7.60 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
BASF India 4039.90
Tata Chemicals 773.85
SRF 2886.20
Pidilite Inds. 1474.70
Deepak Nitrite 1565.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×